Comparison of Flutter and PEP Mask on Chest Clearance, Dyspnea in Elderly Asthmatic Patients
NCT05618873 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30
Last updated 2023-01-26
Summary
This study will be a Randomized controlled and will be conducted in Allied Hospital, Faisalabad. The study will be completed within the duration of 10 months. Convenience sampling study technique will be used to collect the data. The sample size of 30 patients will be taken in this study to find the effect of flutter and PEP mask therapy on chest clearance and dyspnea. Patients will be allocated randomly in two groups and 15 patients in each group. Group A will get flutter device therapy. Group B will get PEP mask treatment. A regular follow up visits to department and a final assessment was made at the end of last week by using questionnaire and resulting improvement was shown in results after completion. Data will be analyzed on SPSS25.
Conditions
Interventions
- DEVICE
-
Flutter device
The flutter was used as follows. Sitting with a straight back and the elbows supported on the table, the patient held the flutter horizontally. The patient inhaled deeply, held their breath for 2 or 3 s and then took the mouthpiece into the mouth and exhaled quietly yet quickly enough to activate the flutter. The patient had to keep their cheeks as stiff as possible. This procedure was repeated 15 times, following which the patient huffed three times and evacuated sputum by a voluntary cough. This sequence was repeated five times. The patient obtained the maximal vibration sensation by tilting the flutter upwards or downwards by a few degrees.
- DEVICE
-
positive expiratory pressure mask
The PEP-mask was used as follows. Sitting with a straight back and the elbows supported on the table, the patient pressed the mask against the face with both hands. After a quiet inhalation, a slow active exhalation followed. The exhalation was restricted by a resistance selected to cause a positive expiratory pressure of 8-12 cmH2O. The patient exhaled 15 times through the mask. Thereafter, the patient huffed three times and evacuated sputum by a voluntary cough. This sequence was repeated five times.
Sponsors & Collaborators
-
Riphah International University
lead OTHER
Principal Investigators
-
Madiha younas, MS · riphah internationl university
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- SINGLE
- Model
- PARALLEL
Eligibility
- Min Age
- 40 Years
- Max Age
- 60 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-05-01
- Primary Completion
- 2023-02-28
- Completion
- 2023-02-28
Countries
- Pakistan
More Related Trials
-
12-Week Study in Adult Subjects With Asthma
NCT01516073 ·Status: COMPLETED ·Phase: PHASE2
-
Peak Flow Monitoring in Older Adults With Asthma
NCT00149474 ·Status: COMPLETED ·Phase: NA
-
To Evaluate Newly Developed Pictogram Cards and Their Utility in Improving Inhaler Techniques in Asthmatic Patients
NCT06562764 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Improving Asthma Treatment Using Inhaler Technology
NCT02977078 ·Status: UNKNOWN ·Phase: NA
-
Interactive Acute Smooth Muscle Effects of Salmeterol and Fluticasone in the Airway
NCT01231230 ·Status: COMPLETED ·Phase: NA
-
Bronchial Ablation for Treatment of Asthma (BATA) Trial
NCT03765307 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Additive Effects of Alternative Nostril Breathing with Pharmacological Management on Dyspnea and Control Pause in Patients with Bronchial Asthma
NCT06609941 ·Status: RECRUITING ·Phase: NA
-
A Pharmacokinetic/Pharmacodynamic Inhaler Comparison Study in Healthy Volunteers
NCT02403713 ·Status: COMPLETED ·Phase: PHASE1
-
Effect of Inhaled Mometasone/Formoterol Versus Inhaled Fluticasone/Salmeterol in Asthma Patients
NCT02415179 ·Status: COMPLETED ·Phase: NA
-
National Mobile Asthma Management System-E Project
NCT02917174 ·Status: COMPLETED ·Phase: NA
-
Post-marketing Safety Monitoring Program of Fluticasone Propionate (FP) in Chinese Subjects With Asthma Aged 1 to <4 Years
NCT03273946 ·Status: COMPLETED
-
Implementation of Evidence-based Breathing Retraining for Patients with Asthma in Region Zealand
NCT05531370 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Induced Sputum Study (0000-065)
NCT00623714 ·Status: COMPLETED ·Phase: PHASE1
-
Flutiform in Treatment of Patients With Asthma in Daily Clinical Practice.
NCT02811315 ·Status: WITHDRAWN
-
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
NCT01225913 ·Status: RECRUITING ·Phase: PHASE4
-
Study to Assess Effect of Next-Generation Propellant MDI on Mucociliary Clearance Vs. HFA Propellant MDI in Healthy Participants
NCT05755932 ·Status: COMPLETED ·Phase: PHASE3
-
Impact of Anti-static Chamber/Mask
NCT00307970 ·Status: COMPLETED ·Phase: PHASE4
-
Salmeterol Xinafoate and Fluticasone Propinate Powder for Inhalation for Asthma
NCT03461627 ·Status: UNKNOWN ·Phase: PHASE3
-
Launching an Asthma Initiative Designed to Improve Asthma Management and Outcomes
NCT02140671 ·Status: UNKNOWN
-
Efficacy and Safety Study of Fluticasone Proponate Inhalation Solution in Adult and Adolescent Asthma
NCT01687283 ·Status: COMPLETED ·Phase: PHASE3
-
LIving BEtteR With asThma studY:: A Multimodal Intervention to Address Multimorbidity in Difficult Asthma
NCT06513117 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Study on the Safety and Efficacy of PA9159 Inhalation Aerosol for the Treatment of Adult Bronchial Asthma
NCT07324707 ·Status: RECRUITING ·Phase: PHASE2
-
Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent® HFA 110 mcg
NCT03879837 ·Status: COMPLETED ·Phase: PHASE3
-
Asthma: Phenotyping Exacerbations 3
NCT05446090 ·Status: UNKNOWN
-
Pharmacokinetic Profile of Four Formulations of Fluticasone Furoate (FF) Using Unit Dose Dry Powder Inhaler (UD-DPI) Compared With FF ELLIPTA® Presentation
NCT02218723 ·Status: COMPLETED ·Phase: PHASE1